--- title: Buy Pradaxa (Dabigatran) 150mg Pills Online description: Pradaxa (Dabigatran) 150mg Pills is a trusted anticoagulant used to prevent strokes and blood clots. Order from our secure pharmacy for reliable delivery. type: product language: en url: https://medsforsale.net/buy-pradaxa-online-en availability: in_stock price_min: 91.99 price_max: 642.99 currency: USD offers: - name: 150mg x 10 caps price: 91.99 - name: 150mg x 20 caps price: 173.99 - name: 150mg x 30 caps price: 228.99 - name: 150mg x 60 caps price: 439.99 - name: 150mg x 90 caps price: 642.99 --- # Buy Pradaxa (Dabigatran) 150mg Pills Online Pradaxa, featuring the active ingredient Dabigatran, is a leading direct thrombin inhibitor developed by Boehringer Ingelheim. It is primarily prescribed to adults to prevent strokes and dangerous blood clots in patients with atrial fibrillation or those recovering from hip or knee replacement surgeries. As a dependable alternative to traditional blood thinners, it offers consistent anticoagulant effects. Our online pharmacy provides a secure and professional service for ordering Pradaxa in 150mg pills, helping you manage your cardiovascular health with confidence. ## Pricing and Options | Dosage | Pack Size | Price (USD) | Price Per Pill | Status | | :--- | :--- | :--- | :--- | :--- | | **150mg** | 10 caps | **$91.99** | $9.20 | In Stock | | **150mg** | 20 caps | **$173.99** | $8.70 | In Stock | | **150mg** | 30 caps | **$228.99** | $7.63 | In Stock | | **150mg** | 60 caps | **$439.99** | $7.33 | In Stock | | **150mg** | 90 caps | **$642.99** | $7.14 | In Stock | [Buy Now](https://medsforsale.net/buy-pradaxa-online-en) ## Introduction Pradaxa (dabigatran etexilate) is an oral anticoagulant prescribed to prevent blood clots that can lead to stroke, systemic embolism, or deep-vein thrombosis. The medication is supplied as a 150 mg pill and belongs to the direct thrombin inhibitor class. It is primarily indicated for atrial fibrillation-related stroke prevention, treatment and secondary prevention of venous thromboembolism (VTE), and for reducing the risk of recurrent VTE after initial therapy. Occasionally clinicians explore off-label uses such as bridging anticoagulation or certain cardiac surgery protocols, but these applications remain unapproved by major regulatory agencies. ## What is Pradaxa? Pradaxa is the generic version of well-known medications, containing the active compound Dabigatran. [our online pharmacy](https://medsforsale.net/buy-pradaxa-online-en) provides this generic alternative as a cost-effective treatment option. Dabigatran etexilate is a pro-drug converted in vivo to dabigatran, a potent, reversible direct inhibitor of thrombin (factor IIa). Developed by Boehringer Ingelheim and first approved by the U.S. Food and Drug Administration (FDA) in 201, Pradaxa transformed the anticoagulation landscape by offering a predictable pharmacokinetic profile without routine laboratory monitoring. In many markets the drug is marketed under brand names such as Pradaxa and other equivalents, but the active ingredient remains identical. ## How Pradaxa Works Dabigatran binds directly to the active site of thrombin, preventing the conversion of fibrinogen to fibrin, a critical step in clot formation. By inhibiting thrombin, the drug reduces both the initiation and propagation of thrombi. After oral ingestion, dabigatran etexilate is rapidly absorbed and converted by esterases to dabigatran; peak plasma concentrations occur within 2 hours, and the effective anticoagulant effect persists for about 12-24 hours. Renal excretion accounts for roughly 80 % of drug elimination, making kidney function a key determinant of dosing and safety. ## Conditions Treated with Pradaxa - **Prevention of stroke and systemic embolism in non-valvular atrial fibrillation (NVAF).** Dabigatran reduces the risk of ischemic stroke by inhibiting clot formation in the left atrium, where turbulent flow predisposes to thrombus development. Large phase III trials (e.g., RE-LY) demonstrated non-inferiority to warfarin with a more favorable bleeding profile. - **Treatment of acute deep-vein thrombosis (DVT) and pulmonary embolism (PE).** In acute VTE, dabigatran interrupts clot propagation, facilitating recanalization of obstructed veins and pulmonary arteries. The drug is approved for initial treatment (6 weeks) followed by long-term secondary prevention (up to 36 months). - **Secondary prevention of recurrent VTE.** After completion of initial therapy, continued dabigatran reduces the incidence of recurrent DVT or PE compared with placebo, supporting extended anticoagulation in high-risk patients. ## Off-Label and Investigational Uses of Pradaxia - **Bridging anticoagulation during temporary interruption of warfarin therapy.** Small observational studies suggest dabigatran can be used to cover short periods when warfarin is stopped for procedures, but formal approval is lacking. - **Post-cardiac surgery thromboprophylaxis.** Some cardiac centers have investigated dabigatran for preventing graft thrombosis after coronary artery bypass grafting (CABG). Evidence remains limited and the practice is not endorsed by regulatory bodies. - **Management of left atrial appendage thrombus.** Case series report successful resolution of thrombus with dabigatran, yet randomized data are absent; use should be confined to specialist-directed protocols. All off-label applications must be undertaken only under the direct supervision of a qualified healthcare professional, as safety and efficacy have not been formally validated by the FDA, EMA, or other agencies. ## Is Pradaxa the Right Medication for You? Pradaxa is most appropriate for adults with: - Documented non-valvular atrial fibrillation who are at moderate-to-high risk of stroke (CHA₂DS₂-VASc ≥ 2). - Acute DVT or PE confirmed by imaging, where rapid anticoagulation is required. - A need for long-term secondary VTE prevention, especially when routine INR monitoring is inconvenient. Contraindications include: - Active pathological bleeding or a history of intracranial hemorrhage. - Severe renal impairment (creatinine clearance < 30 mL/min) because drug clearance is markedly reduced. - Known hypersensitivity to dabigatran or any excipients in the tablet formulation. Patients with mechanical heart valves, hepatic disease with coagulopathy, or those taking strong P-gp inhibitors (e.g., ketoconazole) should avoid dabigatran unless explicitly advised otherwise. ## Risks, Side Effects, and Interactions ### Common - **Gastrointestinal discomfort** (dyspepsia, heartburn). - **Nausea** and occasional vomiting. - **Mild bruising** or ecchymosis at sites of minor trauma. These events are usually self-limiting and can be mitigated by taking the capsule with a full glass of water and remaining upright for at least 30 minutes. ### Rare - **Elevated liver enzymes** (ALT/AST) observed in <1 % of patients. - **Skin rash** or pruritus, indicating a possible hypersensitivity reaction. Monitoring liver function tests periodically is advisable in patients with pre-existing hepatic disease. ### Serious - **Major bleeding**, including gastrointestinal hemorrhage and intracranial bleeding. - **Hemorrhagic stroke**, a life-threatening event with high mortality. - **Allergic anaphylaxis**, though extremely uncommon. Prompt medical attention is essential if any signs of serious bleeding appear, such as hematuria, melena, sudden severe headache, or unexplained weakness. #### Drug-Drug Interactions - **P-glycoprotein (P-gp) inhibitors** (e.g., amiodarone, quinidine, verapamil) can increase dabigatran plasma levels; dose reduction may be required. - **P-gp inducers** (e.g., rifampin, carbamazepine) can lower exposure, potentially reducing efficacy. - **Antiplatelet agents** (aspirin, clopidogrel) and other anticoagulants markedly raise bleeding risk; concurrent use is generally discouraged unless clinically justified. #### Drug-Food Interactions - **High-fat meals** modestly delay absorption but do not significantly affect overall exposure. - **Alcohol** does not interact pharmacokinetically, yet it can increase bleeding propensity and should be limited. Patients should avoid concurrent use of over-the-counter NSAIDs or herbal preparations known to affect coagulation (e.g., ginkgo biloba, garlic supplements). ## Use: Dosing, Missed Dose, Overdose - **Standard dosing** for stroke prevention in NVAF is 150 mg taken orally twice daily with food. For VTE treatment, the recommended initial course is 150 mg twice daily after at least five days of parenteral anticoagulation. - **Renal adjustment**: If creatinine clearance is 30-50 mL/min, a reduced dose of 110 mg twice daily may be prescribed; patients with clearance < 30 mL/min should not use dabigatran. - **Missed dose**: If a dose is forgotten and it has been less than 8 hours since the scheduled time, take the missed tablet immediately. If more than 8 hours have elapsed, skip the missed dose and resume the regular schedule. Do not double-dose. - **Overdose**: In case of suspected overdose, seek emergency care promptly. Activated charcoal is ineffective after absorption; idarucizumab, a specific reversal antibody, can rapidly neutralize dabigatran’s effect in controlled settings. **Practical precautions**: The capsule should be swallowed whole with a full glass of water; remaining upright for a short period minimizes esophageal irritation. Alcoholic beverages do not interfere with drug metabolism but may enhance bleeding risk. Operating heavy machinery or driving is permissible when stable, but patients experiencing dizziness or bleeding should refrain. ## FAQ - **What is the appearance of a 150 mg Pradaxa tablet?** The tablet is a pink, film-coated capsule measuring approximately 12 mm in length. It is marked with “150 mg” on one side for easy identification. - **Can Pradaxa be taken with proton-pump inhibitors (PPIs) to reduce dyspepsia?** Yes, PPIs such as omeprazole can be used concurrently to alleviate gastrointestinal discomfort without affecting dabigatran’s anticoagulant activity. - **How should Pradaxa be stored in hot climates?** Store the medication at controlled room temperature (20-25 °C). In environments exceeding 30 °C, keep the bottle in a cool, dry place away from direct sunlight, such as a refrigerator compartment (do not freeze). - **Is there a need for routine blood monitoring while on Pradaxa?** Routine coagulation monitoring is not required, but periodic renal function assessment is recommended, especially in elderly patients or those with known kidney disease. - **What laboratory test best reflects Pradaxa’s anticoagulant effect?** The diluted thrombin time (dTT) or ecarin clotting time (ECT) provides a quantitative measure of dabigatran activity; standard INR testing is not applicable. - **Can pregnant women use Pradaxa?** Safety data in pregnancy are limited, and the drug is classified as Category B. It should only be used when the potential benefit outweighs the potential risk, and under specialist guidance. - **Does Pradaxa cross the blood-brain barrier?** Minimal penetration occurs; nevertheless, its anticoagulant action can still predispose to intracranial hemorrhage, particularly in patients with pre-existing cerebral lesions. - **How long does it take for normal clotting to return after stopping Pradaxa?** The anticoagulant effect wanes within 12-24 hours after the last dose in individuals with normal renal function, but may be prolonged in renal impairment. - **Are there any travel considerations for patients on Pradaxa?** When flying, maintain regular dosing schedule according to the home time zone. Carry a written statement of medication for customs, and keep the medication in hand luggage to avoid temperature extremes. - **What are the inactive ingredients in the Pradaxa capsule?** The capsule contains microcrystalline cellulose, lactose monohydrate, magnesium stearate, and a gelatin shell. Patients with lactose intolerance should discuss alternatives with their provider. ## Glossary **Direct Thrombin Inhibitor** : A class of anticoagulants that block thrombin’s enzymatic activity, preventing fibrin formation and clot stabilization. **Pro-drug** : An inactive precursor that is metabolized in the body to produce the active therapeutic compound; dabigatran etexilate is converted to dabigatran after oral absorption. **Creatinine Clearance (CrCl)** : An estimate of kidney filtration capacity, expressed in milliliters per minute, used to adjust dosing of renally excreted drugs like dabigatran. **Idarucizumab** : A monoclonal antibody fragment that binds dabigatran with high affinity, providing rapid reversal of its anticoagulant effect during emergencies. ## Buying Pradaxa from [our online pharmacy](https://medsforsale.net/buy-pradaxa-online-en) Patients who encounter high out-of-pocket costs or limited local availability can obtain generic dabigatran through [our online pharmacy](https://medsforsale.net/buy-pradaxa-online-en). By sourcing directly from licensed international suppliers, we are able to offer the medication at prices close to the manufacturer’s wholesale rate, reducing financial barriers without compromising quality. Every batch is verified for authenticity and compliance with Good Manufacturing Practices, guaranteeing that you receive a product that meets strict safety standards. Discreet packaging and secure shipping options protect your privacy, while our reliable logistics network typically delivers express orders within seven days and standard shipments within three weeks. Because we act as a pharmacy-broker service, we can navigate complex import regulations on your behalf, providing a streamlined, confidential solution for patients who otherwise face obstacles accessing this essential therapy. ## Disclaimer The information presented about Pradaxa is intended for general educational purposes and does not replace professional medical advice. All decisions regarding therapy, including any off-label applications, must be made under the supervision of a qualified health-care provider. Readers are presumed to be responsible adults capable of making informed health choices. [our online pharmacy](https://medsforsale.net/buy-pradaxa-online-en) offers access to Pradaxa for individuals who may have limited availability through conventional pharmacy channels, insurance formularies, or who are seeking cost-effective generic alternatives. Consultation with your physician is essential before initiating, modifying, or discontinuing any medication.